The influence of MRP2, MDR1 and OATP1B3 polymorphism on telmisartan's pharmacokinetics and pharmacodynamics.
Phase of Trial: Phase IV
Latest Information Update: 22 Apr 2016
At a glance
- Drugs Telmisartan (Primary)
- Indications Hypertension
- Focus Pharmacogenomic; Pharmacokinetics
- 08 Jan 2012 Actual initiation date changed from (1 Jun 2010) to (1 May 2010 ) as reported by Chinese Clinical Trial Register.
- 21 Jun 2010 New trial record